Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.63 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11178746 | 0.88 | AAK1 (0.55) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL11191386 | 0.87 | AAK1 (0.54) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL14920813 | 0.85 | BCHE (0.49) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL2352584 | 0.84 | MEN1 (0.56) | RAB9ANPC1SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL2133754 | 0.81 | BCHE (0.61) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL8286810 | 0.81 | BCHE (0.61) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL1343363 | 0.81 | BCHE (0.61) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL9477024 | 0.81 | BCHE (0.61) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL334233 | 0.81 | BCHE (0.61) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL10254172 | 0.81 | BCHE (0.72) | BCHEMDM2HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788326-B1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RES & DEV (FR) | 2019-04-24 | — | — | EP | disclosed |
| US-9732044-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9732044-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9732044-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-08-15 | — | — | US | disclosed |
| US-20170066725-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-03-09 | — | — | US | disclosed |
| US-20170066725-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-03-09 | — | — | US | disclosed |
| US-20170066725-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-03-09 | — | — | US | disclosed |
| US-9452120-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9452120-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-09-27 | — | — | US | disclosed |
| US-9452120-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2788326-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | Galderma Research & Development (FR) | 2014-10-15 | — | — | EP | disclosed |
| CN-104039767-A | N- (pyridin-4-yl) amides and N- (pyrimidin-4-yl) amides and their pharmaceutical and cosmetic use | GALDERMA RES & DEV | 2014-09-10 | — | — | CN | disclosed |
| US-20140234245-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20140234245-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20140234245-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-21 | — | — | US | disclosed |
| WO-2013064681-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064681-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-10 | — | — | WO | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
| US-4024249-A | FOR COMBATTING MICROORGANISMS | CIBA-GEIGY CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234245-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | NR5A1, AR, CYP19A1 | BCHE 3935/4885MDM2 3105/4885HDAC3 1295/4885 |
| US-20170066725-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | AR, NR5A1, PPARA | BCHE 3657/4885MDM2 3599/4885HDAC3 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.